Welcome to our dedicated page for Dbv Technologies S A SEC filings (Ticker: DBVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading DBV Technologies’ SEC filings can feel like decoding a clinical protocol: pages of Phase 3 trial data, FDA queries, and cash-runway tables that bury the numbers investors need. If you have ever wondered where to locate “DBV Technologies insider trading Form 4 transactions” or how a single adverse-event footnote could change the company’s valuation, this page turns that challenge into clarity.
Stock Titan’s platform surfaces every document the moment it hits EDGAR and layers in AI-powered summaries that translate biotech jargon into plain English. Compare cash-burn trends in the latest “DBV Technologies quarterly earnings report 10-Q filing,” follow “DBV Technologies Form 4 insider transactions real-time,” and get “DBV Technologies SEC filings explained simply” without opening a spreadsheet. Our analysis ties each filing type to issues unique to a development-stage allergen patch maker: the viability of Viaskin’s pivotal trials, milestone payments from partners, and regulatory milestones outlined in every “DBV Technologies 8-K material events explained.”
Use cases are practical. Track management confidence by monitoring “DBV Technologies executive stock transactions Form 4,” review cash-flow assumptions with our “DBV Technologies earnings report filing analysis,” and see dilution risk before secondary offerings appear. Need the big picture? Our AI condenses the 200-page “DBV Technologies annual report 10-K simplified,” highlights FDA correspondence, and even flags the “DBV Technologies proxy statement executive compensation” section so you can benchmark pay against pipeline progress. Whether you’re assessing immunotherapy trial endpoints or planning to trade around catalyst dates, “understanding DBV Technologies SEC documents with AI” starts here—and happens in seconds.
Venrock-affiliated funds and related entities collectively report beneficial ownership of 14,286,553 ADSs of DBV Technologies S.A., representing 9.8% of the class as of June 30, 2025. The filing aggregates direct ADS holdings and pre-funded warrants exercisable for 9,150,000 Ordinary Shares. The percent calculation uses 136,948,872 Ordinary Shares outstanding plus the 9,150,000 issuable on exercise of the pre-funded warrants. Multiple Venrock vehicles and two individual reporting persons (Nimish Shah and Bong Y. Koh) are members of the reporting group; managing entities (VHCP Management II/III/EG) serve as general partners or managers for the funds. Signatures and powers of attorney are included by reference.
Adage Capital Management, L.P., Robert Atchinson and Phillip Gross report owning 14,614,449 Ordinary Shares of DBV Technologies S.A., representing 9.99% of the outstanding Ordinary Shares based on the companys reported share count of 136,948,872. The disclosed position includes Ordinary Shares underlying American Depositary Shares and shares issuable upon exercise of warrants, and voting and dispositive power is reported as shared rather than sole.
The filing is a Schedule 13G, which the Reporting Persons certify reflects passive holdings held in the ordinary course of business and not for the purpose of changing or influencing control. Each ADS represents five Ordinary Shares and the cover disclosure explains the stake calculation assumes exercise of certain warrants held by the reporting fund.
DBV Technologies announced a significant milestone in its clinical research program with the first subject screening in the COMFORT Toddlers Supplemental Safety Study, focusing on peanut-allergic children aged 1-3 years old. This development marks an important step in the company's research into peanut allergy treatments.
The company, which trades on Nasdaq under symbol DBVT through American Depositary Shares (each representing five ordinary shares), filed this 8-K to report the initiation of this clinical study. The announcement was made via press release on June 25, 2025.
Key filing details:
- The study specifically targets toddlers between 1-3 years old with peanut allergies
- The filing includes two exhibits: the press release (99.1) and Cover Page Interactive Data File
- The document was signed by CFO Virginie Boucinha
DBV Technologies has filed a Form S-8 registration statement to register securities related to its 2025 Stock Option Plan and 2025 Free Share Plan. The company, headquartered in Châtillon, France, is classified as a non-accelerated filer and smaller reporting company.
Key aspects of the filing include:
- Registration incorporates previous S-8 filings from October 2014, November 2023, and July 2024
- Includes the company's Annual Report for FY2024 and Q1 2025 Quarterly Report
- Maintains liability insurance for directors and officers with contractual indemnification provisions
- French law prohibits limiting director liability but allows insurance against civil liabilities
The registration is signed by CEO Daniel Tassé and includes authorization from the full board of directors. Michele Robertson serves as the authorized U.S. representative in her capacity as Chief Legal Officer. The filing demonstrates DBV Technologies' commitment to employee equity compensation while maintaining compliance with both U.S. and French regulatory requirements.
FAQ
What is the current stock price of Dbv Technologies S A (DBVT)?
What is the market cap of Dbv Technologies S A (DBVT)?
